Switch theme
Sign up to access all valuation multiples
Chengdu Kanghua Biological Products Co Ltd is engaged in research, development, production, sales and technical services of biological products for prevention, and the existing products include Group ACYW135 Meningococcal Polysaccharide Vaccine-Maikexin, Rabies Vaccine (human diploid cell) for Human Use, freeze-dried - HDCV. The company's products include ACYW135 Meningococcal Polysaccharide Vaccine; and Rabies Vaccine.
2004
n/a
LTM Revenue $205M
LTM EBITDA $79.0M
$958M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Chengdu Kanghua has a last 12-month revenue (LTM) of $205M and a last 12-month EBITDA of $79.0M.
In the most recent fiscal year, Chengdu Kanghua achieved revenue of $199M and an EBITDA of $74.6M.
Chengdu Kanghua expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Chengdu Kanghua valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $205M | XXX | $199M | XXX | XXX | XXX |
| Gross Profit | $193M | XXX | $187M | XXX | XXX | XXX |
| Gross Margin | 94% | XXX | 94% | XXX | XXX | XXX |
| EBITDA | $79.0M | XXX | $74.6M | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| EBIT | $70.1M | XXX | $76.5M | XXX | XXX | XXX |
| EBIT Margin | 34% | XXX | 38% | XXX | XXX | XXX |
| Net Profit | $58.7M | XXX | $55.3M | XXX | XXX | XXX |
| Net Margin | 29% | XXX | 28% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Chengdu Kanghua's stock price is CNY 58 (or $8).
Chengdu Kanghua has current market cap of CNY 7.7B (or $1.1B), and EV of CNY 6.9B (or $958M).
See Chengdu Kanghua trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $958M | $1.1B | XXX | XXX | XXX | XXX | $0.44 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Chengdu Kanghua has market cap of $1.1B and EV of $958M.
Chengdu Kanghua's trades at 4.8x EV/Revenue multiple, and 12.8x EV/EBITDA.
Equity research analysts estimate Chengdu Kanghua's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Chengdu Kanghua has a P/E ratio of 18.1x.
See valuation multiples for Chengdu Kanghua and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $1.1B | XXX | $1.1B | XXX | XXX | XXX |
| EV (current) | $958M | XXX | $958M | XXX | XXX | XXX |
| EV/Revenue | 4.7x | XXX | 4.8x | XXX | XXX | XXX |
| EV/EBITDA | 12.1x | XXX | 12.8x | XXX | XXX | XXX |
| EV/EBIT | 13.7x | XXX | 12.5x | XXX | XXX | XXX |
| EV/Gross Profit | 5.0x | XXX | n/a | XXX | XXX | XXX |
| P/E | 18.1x | XXX | 19.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | 16.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialChengdu Kanghua's last 12 month revenue growth is 7%
Chengdu Kanghua's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Chengdu Kanghua's rule of 40 is 47% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Chengdu Kanghua's rule of X is 56% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Chengdu Kanghua and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 7% | XXX | 7% | XXX | XXX | XXX |
| EBITDA Margin | 39% | XXX | 38% | XXX | XXX | XXX |
| EBITDA Growth | 14% | XXX | -1% | XXX | XXX | XXX |
| Rule of 40 | 47% | XXX | 45% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 35% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 9% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 56% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Chengdu Kanghua acquired XXX companies to date.
Last acquisition by Chengdu Kanghua was XXXXXXXX, XXXXX XXXXX XXXXXX . Chengdu Kanghua acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Chengdu Kanghua founded? | Chengdu Kanghua was founded in 2004. |
| Where is Chengdu Kanghua headquartered? | Chengdu Kanghua is headquartered in China. |
| Is Chengdu Kanghua publicy listed? | Yes, Chengdu Kanghua is a public company listed on SHE. |
| What is the stock symbol of Chengdu Kanghua? | Chengdu Kanghua trades under 300841 ticker. |
| When did Chengdu Kanghua go public? | Chengdu Kanghua went public in 2020. |
| Who are competitors of Chengdu Kanghua? | Similar companies to Chengdu Kanghua include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Chengdu Kanghua? | Chengdu Kanghua's current market cap is $1.1B |
| What is the current revenue of Chengdu Kanghua? | Chengdu Kanghua's last 12 months revenue is $205M. |
| What is the current revenue growth of Chengdu Kanghua? | Chengdu Kanghua revenue growth (NTM/LTM) is 7%. |
| What is the current EV/Revenue multiple of Chengdu Kanghua? | Current revenue multiple of Chengdu Kanghua is 4.7x. |
| Is Chengdu Kanghua profitable? | Yes, Chengdu Kanghua is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Chengdu Kanghua? | Chengdu Kanghua's last 12 months EBITDA is $79.0M. |
| What is Chengdu Kanghua's EBITDA margin? | Chengdu Kanghua's last 12 months EBITDA margin is 39%. |
| What is the current EV/EBITDA multiple of Chengdu Kanghua? | Current EBITDA multiple of Chengdu Kanghua is 12.1x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
